Dirk Blom
Impact in
- Surgery top 0.1%
- Lipoproteins and Cardiovascular Health
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
- Surgery 120
- Lipoproteins and Cardiovascular Health 116
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 26
- Co-authors
- Frederick J. Raal (50 shared papers)Scott M. Wasserman (16 shared papers)A. David Marais (33 shared papers)Robert C. Scott (10 shared papers)Evan A. Stein (14 shared papers)Michael J. Koren (9 shared papers)Daniel Gaudet (18 shared papers)Christie M. Ballantyne (3 shared papers)
- Journals
- Journal of clinical lipidology (19 papers)Atherosclerosis (14 papers)Journal of the American College of Cardiology (10 papers)Circulation (9 papers)Atherosclerosis Supplements (5 papers)
- Partner nations
- South AfricaUnited StatesFrance
In The Last Decade
Dirk Blom
152 papers receiving 8.3k citations
Dirk Blom's Hit Papers
Peers
Comparison fields: 5 of 123
- Surgery 5.9k
- Endocrinology, Diabetes and Metabolism 1.6k
- Cancer Research 1.3k
- Cardiology and Cardiovascular Medicine 1.6k
- Economics and Econometrics 1.1k
Countries citing papers authored by Dirk Blom
This map shows the geographic impact of Dirk Blom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Blom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Blom more than expected).
Fields of papers citing papers by Dirk Blom
This network shows the impact of papers produced by Dirk Blom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Blom. The network helps show where Dirk Blom may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk Blom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 161 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Hit paper breakdown → | 2015 | 1146 |
| 2 | Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2010 | 735 |
| 3 | A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia Hit paper breakdown → | 2014 | 583 |
| 4 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 572 |
| 5 | Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Hit paper breakdown → | 2012 | 566 |
| 6 | Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome Hit paper breakdown → | 2019 | 447 |
| 7 | ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Hit paper breakdown → | 2015 | 428 |
| 8 | Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Hit paper breakdown → | 2015 | 327 |
| 9 | 2011 | 322 | |
| 10 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) Hit paper breakdown → | 2014 | 287 |
| 11 | 2011 | 271 | |
| 12 | 2016 | 174 | |
| 13 | 2017 | 164 | |
| 14 | 2010 | 135 | |
| 15 | 2020 | 128 | |
| 16 | 2020 | 124 | |
| 17 | 2016 | 96 | |
| 18 | 2017 | 78 | |
| 19 | 2015 | 78 | |
| 20 | 2017 | 76 |
About Dirk Blom
Dirk Blom is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cancer Research, Cardiology and Cardiovascular Medicine and Economics and Econometrics, having authored 161 papers that have together received 8.6k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (116 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers), Lipid metabolism and disorders (24 papers), Cancer, Lipids, and Metabolism (23 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical Economics and Policy (10 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). The work is most often cited by research in Surgery (5.9k citations), Endocrinology, Diabetes and Metabolism (1.6k citations), Cancer Research (1.3k citations), Cardiology and Cardiovascular Medicine (1.6k citations) and Economics and Econometrics (1.1k citations). Dirk Blom has collaborated with scholars based in South Africa, United States and France. Frequent co-authors include Frederick J. Raal, Scott M. Wasserman, A. David Marais, Robert C. Scott, Evan A. Stein, Michael J. Koren, Daniel Gaudet, Christie M. Ballantyne, Robert P. Giugliano and Marc S. Sabatine. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, Journal of the American College of Cardiology, Circulation and Atherosclerosis Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.